Bayer's Prostate Cancer Drug- Alpharadin Successful in Phase III Trials

by Dr. Trupti Shirole on  June 6, 2011 at 10:00 PM Cancer News
RSS Email Print This Page Comment
Font : A-A+

German pharmaceutical company Bayer AG has been asked to stop the phase III trials of the drug Alpharadin. Patients who were receiving placebo will be offered the new medicine. The safety and tolerability of Alpharadin were consistent during Phase I and Phase II trial outcomes.
 Bayer's Prostate Cancer Drug- Alpharadin Successful in Phase III Trials
Bayer's Prostate Cancer Drug- Alpharadin Successful in Phase III Trials

Alpharadin, or radium-223 chloride is exclusively licensed from Norwegian partner Algeta ASA. The drug met its primary endpoint by improving overall survival significantly in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.

The median overall survival rate was 14 months for patients treated with Alpharadin, compared with 11.2 months.


Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Hematuria Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive